Roche currently has several different therapeutic antibody technologies in early clinical development which in the future could hopefully be a strong pillar in addressing the complexity of targeting more than 250 cancer diseases.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
No comment yet.
Sign up to comment
Krishan Maggon 's curator insight,
March 3, 2015 1:00 PM
Sujin Kang, Toshio Tanaka, and Tadamitsu KishimotoTherapeutic uses of anti-interleukin-6 receptor antibody
Int. Immunol. (2015) 27 (1): 21-29 doi:10.1093/intimm/dxu081 |
Krishan Maggon 's curator insight,
April 11, 2015 9:30 AM
Drug Discovery Today Volume 18, Issues 17–18, September 2013, Pages 872–879 Review Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumabHans C. Ebbers1, Peter J.K. van Meer3, Ellen H.M. Moors2, Aukje K. Mantel-Teeuwisse1, , , Hubert G.M. Leufkens1, Huub Schellekens2, 3Available online 18 May 2013 doi:10.1016/j.drudis.2013.05.004
Krishan Maggon 's curator insight,
October 28, 2014 2:46 AM
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapyVijay U. Rao MD, PhD1,†, Andrey Pavlov PhD2, Micki Klearman MD1,*, David Musselman MD1, Jon T. Giles MD, MPH3,Joan M. Bathon MD3, Naveed Sattar FRCPath, PhD4 andJanet S. Lee PhD5,‡
DOI: 10.1002/art.38920 Copyright © 2014 American College of Rheumatology Issue Arthritis & RheumatologyAccepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) |